Skip to main content
. Author manuscript; available in PMC: 2022 Oct 30.
Published in final edited form as: Eur J Cancer. 2022 Jan 19;163:108–118. doi: 10.1016/j.ejca.2021.12.024

Fig. 3. Kaplan–Meier curves of the survival probability over time after starting immune checkpoint inhibitor therapy.

Fig. 3.

Panel A shows patients with genitourinary cancer who were taking Lisinopril and controls patients who were on non–renin–angiotensin–aldosterone system (RAAS) inhibitor anti-hypertensive therapy. Panel B shows overall survival in patients who received ICI and VEGF-targeted therapy.